Christoph Lange

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7033028/publications.pdf

Version: 2024-02-01

344	22,377	10070 75	13274 135
papers	citations	h-index	g-index

393	393	393	22694
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emergence of bedaquiline resistance in a high tuberculosis burden country. European Respiratory Journal, 2022, 59, 2100621.	3.1	48
2	100 years of Mycobacterium bovis bacille Calmette-GuÃ©rin. Lancet Infectious Diseases, The, 2022, 22, e2-e12.	4.6	87
3	A Smoothed Version of the Lassosum Penalty for Fitting Integrated Risk Models Using Summary Statistics or Individual-Level Data. Genes, 2022, 13, 112.	1.0	1
4	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	4.6	51
5	The need for effective drugs for TB prevention: set your goals high, and donÂ´t stop till you get there. International Journal of Tuberculosis and Lung Disease, 2022, 26, 85-88.	0.6	1
6	Reply to Neupane etÂal.: Replication study of ADâ€associated rare variants. Alzheimer's and Dementia, 2022, , .	0.4	0
7	The influence of unmeasured confounding on the MR Steiger approach. Genetic Epidemiology, 2022, 46, 139-141.	0.6	6
8	Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. European Respiratory Journal, 2022, 60, 2102263.	3.1	17
9	Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1142-1144.	2.5	10
10	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. Journal of Infection, 2022, 84, 834-872.	1.7	8
11	Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimerâ€™s disease-associated genes: DTNB and DLG2. Molecular Psychiatry, 2022, 27, 1963-1969.	4.1	9
12	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. European Respiratory Journal, 2022, 59, 2102950.	3.1	9
13	War in Ukraine: an immense threat to the fight against tuberculosis. European Respiratory Journal, 2022, 59, 2200493.	3.1	8
14	Selection bias when inferring the effect direction in Mendelian randomization. Genetic Epidemiology, 2022, 46, 341-343.	0.6	0
15	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	3.1	15
16	Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing. Genome Medicine, 2022, 14, 52.	3.6	14
17	Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nature Communications, 2022, 13, .	5.8	36
18	Clinical Evaluation of a Line-Probe Assay for Tuberculosis Detection and Drug-Resistance Prediction in Namibia. Microbiology Spectrum, 2022, 10, .	1.2	1

#	Article	IF	Citations
19	Assessing the contribution of rare genetic variants to phenotypes of chronic obstructive pulmonary disease using whole-genome sequence data. Human Molecular Genetics, 2022, 31, 3873-3885.	1.4	2
20	Pathogenesis of tuberculosis: the 1930 LÃ¼beck disaster revisited. European Respiratory Review, 2022, 31, 220046.	3.0	4
21	Clinical standards for drug-susceptible pulmonary TB. International Journal of Tuberculosis and Lung Disease, 2022, 26, 592-604.	0.6	6
22	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
23	An interaction of the 17q12â€21 locus with mold exposure in childhood asthma. Pediatric Allergy and Immunology, 2021, 32, 373-376.	1.1	0
24	A novel locus for exertional dyspnoea in childhood asthma. European Respiratory Journal, 2021, 57, 2001224.	3.1	4
25	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. European Respiratory Journal, 2021, 58, 2003492.	3.1	27
26	The Role of SNP Interactions when Determining Independence of Novel Signals in Genetic Association Studiesâ€"An Application to ARG1 and Bronchodilator Response. Journal of Personalized Medicine, 2021, 11, 145.	1.1	0
27	Use and impact of molecular methods for detecting drugâ€resistant TB. International Journal of Tuberculosis and Lung Disease, 2021, 25, 157-159.	0.6	1
28	Tuberculosis endotypes to guide stratified host-directed therapy. Med, 2021, 2, 217-232.	2.2	24
29	Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing. Clinical Infectious Diseases, 2021, 73, 1194-1202.	2.9	21
30	Impact of lung function on treatment outcome in patients with TB. International Journal of Tuberculosis and Lung Disease, 2021, 25, 277-284.	0.6	5
31	A fast and efficient smoothing approach to Lasso regression and an application in statistical genetics: polygenic risk scores for chronic obstructive pulmonary disease (COPD). Statistics and Computing, 2021, 31, 1.	0.8	3
32	Wholeâ€genome sequencing reveals new Alzheimer's diseaseâ€"associated rare variants in loci related to synaptic function and neuronal development. Alzheimer's and Dementia, 2021, 17, 1509-1527.	0.4	50
33	Perspectives for systems biology in the management of tuberculosis. European Respiratory Review, 2021, 30, 200377.	3.0	13
34	Seroprevalence of Aspergillus-Specific IgG Antibody among Mozambican Tuberculosis Patients. Journal of Fungi (Basel, Switzerland), 2021, 7, 595.	1.5	7
35	Sorry for the delay. Clinical Microbiology and Infection, 2021, 27, 941-943.	2.8	0
36	WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis. Journal of Clinical Investigation, 2021, 131, .	3.9	17

#	Article	IF	Citations
37	Pathogen-free diagnosis of tuberculosis. Lancet Infectious Diseases, The, 2021, 21, 1066.	4.6	0
38	Alveolar macrophages from persons living with HIV show impaired epigenetic response to Mycobacterium tuberculosis. Journal of Clinical Investigation, 2021, 131, .	3.9	19
39	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 713-722.	2.5	22
40	A unifying framework for rare variant association testing in family-based designs, including higher criticism approaches, SKATs, and burden tests. Bioinformatics, 2021, 36, 5432-5438.	1.8	7
41	Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. European Respiratory Journal, 2021, 57, 2002544.	3.1	15
42	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. International Journal of Tuberculosis and Lung Disease, 2021, 25, 797-813.	0.6	78
43	Improving the diagnosis of tuberculous meningitis: good, but not good enough. Clinical Microbiology and Infection, 2020, 26, 134-136.	2.8	4
44	A flexible and nearly optimal sequential testing approach to randomized testing: QUICKâ€STOP. Genetic Epidemiology, 2020, 44, 139-147.	0.6	4
45	Intensified adjunctive corticosteroid therapy for CNS tuberculomas. Infection, 2020, 48, 289-293.	2.3	6
46	Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. European Respiratory Journal, 2020, 55, 1901467.	3.1	55
47	Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respiratory Medicine, 2020, 173, 106164.	1.3	21
48	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine, 2020, 26, 1941-1949.	15.2	58
49	Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine. International Journal of Tuberculosis and Lung Disease, 2020, 24, 485-491.	0.6	15
50	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, The, 2020, 396, 402-411.	6.3	49
51	COVID-19 -Tuberculosis interactions: When dark forces collide. Indian Journal of Tuberculosis, 2020, 67, S155-S162.	0.3	47
52	Pack-Years of Cigarette Smoking Mediates More of the Effect of Chromosome 15q25 on Pulmonary Function Than Smoking Intensity and Duration. , 2020, , .		0
53	Perspective for Precision Medicine for Tuberculosis. Frontiers in Immunology, 2020, 11, 566608.	2.2	35
54	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, 905-913.	2.9	357

#	Article	IF	Citations
55	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 383-394.	5.2	155
56	The effects of misspecification of the mediator and outcome in mediation analysis. Genetic Epidemiology, 2020, 44, 400-403.	0.6	5
57	Challenging the management of drug-resistant tuberculosis â€“ Authors' reply. Lancet, The, 2020, 395, 783-784.	6.3	1
58	Identification of Novel Alzheimerâ€™s Disease Loci Using Sex-Specific Family-Based Association Analysis of Whole-Genome Sequence Data. Scientific Reports, 2020, 10, 5029.	1.6	31
59	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal, 2020, 56, 2000535.	3.1	336
60	Changes in treatment for multidrug-resistant tuberculosis according to national income. European Respiratory Journal, 2020, 56, 2001394.	3.1	4
61	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, e1-e36.	2.9	367
62	Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1564-1568.	2.5	59
63	Title is missing!. , 2020, 15, e0238619.		0
64	Title is missing!. , 2020, 15, e0238619.		0
65	Title is missing!. , 2020, 15, e0238619.		0
66	Title is missing!. , 2020, 15, e0238619.		0
67	Management of patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 645-662.	0.6	55
68	X Chromosome Genetic Associations in COPD. , 2019, , .		0
69	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	5.2	92
70	Management of drug-resistant tuberculosis. Lancet, The, 2019, 394, 953-966.	6.3	186
71	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. Chest, 2019, 156, 1068-1079.	0.4	5
72	Molecular-based tuberculosis drug susceptibility testing: one size fits all?. International Journal of Tuberculosis and Lung Disease, 2019, 23, 879-880.	0.6	3

#	Article	IF	Citations
73	The MDR-TB epidemicâ€"a status report. International Journal of Tuberculosis and Lung Disease, 2019, 23, 121-122.	0.6	2
74	Cigarette smoking and culture conversion in patients with susceptible and M/XDR-TB. International Journal of Tuberculosis and Lung Disease, 2019, 23, 93-98.	0.6	11
75	Burden and Characteristics of the Comorbidity Tuberculosisâ€"Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infectious Diseases, 2019, 6, ofy337.	0.4	12
76	Failing treatment of multidrug-resistant tuberculosis: a matter of definition. International Journal of Tuberculosis and Lung Disease, 2019, 23, 522-524.	0.6	10
77	New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 514-515.	2.5	10
78	Tuberculous mediastinal lymphadenopathy: Reaching the target. Respirology, 2019, 24, 622-623.	1.3	2
79	Smoking Mediates the Effect of Both Rare and Common Variants in Chromosome 15q25 Region on Pulmonary Function. , 2019, , .		0
80	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	3.1	54
81	A comparison of popular TDTâ€generalizations for familyâ€based association analysis. Genetic Epidemiology, 2019, 43, 300-317.	0.6	7
82	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal, 2019, 53, 1802089.	3.1	9
83	Clofazimine for the treatment of multidrug-resistant tuberculosis. Clinical Microbiology and Infection, 2019, 25, 128-130.	2.8	19
84	Integrative Genomics Analysis Identifies ACVR1B as a Candidate Causal Gene of Emphysema Distribution. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 388-398.	1.4	15
85	Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 379-386.	2.5	27
86	Relapse-free cure from multidrug-resistant tuberculosis in Germany. European Respiratory Journal, 2018, 51, 1702122.	3.1	17
87	Pan-tuberculosis regimens: an argument against. Lancet Respiratory Medicine,the, 2018, 6, 240-242.	5.2	17
88	Drugâ€resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology, 2018, 23, 656-673.	1.3	159
89	Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with <i>Pneumocystis jirovecii</i> Pneumonia. Respiration, 2018, 96, 52-65.	1.2	121
90	A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infectious Diseases, The, 2018, 18, 431-440.	4.6	121

#	Article	IF	Citations
91	Pulmonary Diseases in Refugees and Migrants in Europe. Respiration, 2018, 95, 273-286.	1.2	6
92	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respiratory Medicine,the, 2018, 6, 246-248.	5.2	11
93	Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. European Respiratory Journal, 2018, 51, 1702189.	3.1	12
94	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 2018, 24, e1-e38.	2.8	942
95	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	3.1	159
96	Recent controversies about <scp>MDR</scp> and <scp>XDRâ€TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDRâ€TB</scp> regimen and bedaquiline for all with <scp>MDRâ€TB</scp>?. Respirology, 2018, 23, 36-45.	1.3	52
97	Family-based tests for associating haplotypes with general phenotype data. Genetic Epidemiology, 2018, 42, 123-126.	0.6	4
98	What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	83
99	Revising the definition of extensively drug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2018, 6, 893-895.	5.2	12
100	Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. Frontiers in Microbiology, 2018, 9, 2223.	1.5	23
101	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	1.6	75
102	Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathogens, 2018, 14, e1007297.	2.1	43
103	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
104	Perspectives for personalized therapy for patients with multidrugâ€resistant tuberculosis. Journal of Internal Medicine, 2018, 284, 163-188.	2.7	33
105	PolyGEE: a generalized estimating equation approach to the efficient and robust estimation of polygenic effects in large-scale association studies. Biostatistics, 2018, 19, 295-306.	0.9	5
106	Whole-Genome Sequencing in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 614-622.	1.4	22
107	Treatment responses in multidrug-resistant tuberculosis in Germany. International Journal of Tuberculosis and Lung Disease, 2018, 22, 399-406.	0.6	8
108	Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. Respiration, 2018, 96, 283-301.	1.2	42

#	Article	IF	Citations
109	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. Human Molecular Genetics, 2018, 27, 3801-3812.	1.4	32
110	Reply to Dookie et al., â€œWhole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosisâ€. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	1
111	An Unexpected Endobronchial Mass Appearing During Bronchoscopy. Chest, 2018, 154, e13-e21.	0.4	1
112	Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration, 2018, 96, 159-170.	1.2	85
113	Reflections on the State of the Art series on TB and migration, and the way forward. International Journal of Tuberculosis and Lung Disease, 2018, 22, 829-829.	0.6	0
114	Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878â€“1940. International Journal of Tuberculosis and Lung Disease, 2018, 22, 972-982.	0.6	42
115	Epidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997â€“2017. Journal of Travel Medicine, 2018, 25, .	1.4	27
116	Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmetteâ€“GuÃ©rin Vaccination. Frontiers in Immunology, 2018, 9, 1708.	2.2	5
117	Mission impossible: the End TB strategy. International Journal of Tuberculosis and Lung Disease, 2018, 22, 121-122.	0.6	5
118	QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. European Respiratory Journal, 2018, 52, 1800537.	3.1	34
119	DISCREPANCY ACROSS PHENOTYPIC AND GENOTYPIC RESULTS OF DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS. , 2018, , .		0
120	Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. European Respiratory Journal, 2017, 49, 1601855.	3.1	94
121	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	1.4	55
122	Geneâ€based segregation method for identifying rare variants in familyâ€based sequencing studies. Genetic Epidemiology, 2017, 41, 309-319.	0.6	14
123	Characterization of patients with chronic pulmonary aspergillosis according to the new <scp>ESCMID</scp>/<scp>ERS</scp>/<scp>ECMM</scp> and <scp>IDSA</scp> guidelines. Mycoses, 2017, 60, 136-142.	1.8	40
124	A general approach to testing for pleiotropy with rare and common variants. Genetic Epidemiology, 2017, 41, 163-170.	0.6	17
125	Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points. International Journal of Tuberculosis and Lung Disease, 2017, 21, 624-636.	0.6	113
126	Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1700742.	3.1	32

#	Article	IF	Citations
127	Treatment outcomes of MDR-TB and HIV co-infection in Europe. European Respiratory Journal, 2017, 49, 1602363.	3.1	17
128	Joint efforts urgently needed at times of emerging tuberculosis drug resistance. Clinical Microbiology and Infection, 2017, 23, 129-130.	2.8	2
129	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
130	Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1222-1224.	2.5	11
131	Reporting Correct p Values in VEGAS Analyses. Twin Research and Human Genetics, 2017, 20, 257-259.	0.3	3
132	On the association analysis of genomeâ€sequencing data: A spatial clustering approach for partitioning the entire genome into nonoverlapping windows. Genetic Epidemiology, 2017, 41, 332-340.	0.6	10
133	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	3.1	20
134	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. Respiratory Medicine, 2017, 132, 68-75.	1.3	7
135	High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. European Respiratory Journal, 2017, 50, 1701340.	3.1	5
136	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490.	2.5	2
137	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project. ERJ Open Research, 2017, 3, 00092-2017.	1.1	22
138	Identification of genetic outliers due to sub-structure and cryptic relationships. Bioinformatics, 2017, 33, 1972-1979.	1.8	19
139	Chronic Cough and Severe Weight Loss in a 55-Year-Old Previously Healthy Man. Clinical Infectious Diseases, 2017, 65, 349-351.	2.9	3
140	Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. Infection, 2017, 45, 269-276.	2.3	32
141	Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs. Tuberculosis, 2017, 102, 31-33.	0.8	3
142	Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Microbiology and Infection, 2017, 23, 131-140.	2.8	47
143	Risk for latent and active tuberculosis in Germany. Infection, 2017, 45, 283-290.	2.3	22
144	A standardised method for interpreting the association between mutations and phenotypic drug resistance inMycobacterium tuberculosis. European Respiratory Journal, 2017, 50, 1701354.	3.1	273

#	Article	IF	Citations
145	Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of thekatG315T mutation. European Respiratory Journal, 2017, 50, 1701752.	3.1	5
146	Pulmonary immune responses to Mycobacterium tuberculosis in exposed individuals. PLoS ONE, 2017, 12, e0187882.	1.1	8
147	MDR-TB in Eastern Europe in the era of the TB elimination action framework. International Journal of Tuberculosis and Lung Disease, 2017, 21, 2-3.	0.6	5
148	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	1.1	12
149	Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS ONE, 2016, 11, e0155968.	1.1	22
150	Viral Load and Risk of Tuberculosis in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e51-e53.	0.9	10
151	In reply. International Journal of Tuberculosis and Lung Disease, 2016, 20, 424-424.	0.6	0
152	More on Treatment Outcomes in Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2016, 375, 2609-2611.	13.9	9
153	High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens. Annals of the American Thoracic Society, 2016, 13, 1271-1278.	1.5	17
154	Design of tuberculosis vaccine trials under financial constraints. Expert Review of Vaccines, 2016, 15, 799-801.	2.0	6
155	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	3.1	27
156	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1029-1031.	2.5	71
157	State-of-the-Art Series on Precision Medicine in Respiratory Diseases. Respiration, 2016, 92, 197-198.	1.2	1
158	Treatment Outcomes in Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2016, 375, 1103-1105.	13.9	73
159	Î²-Lactams against Tuberculosis â€" New Trick for an Old Dog?. New England Journal of Medicine, 2016, 375, 393-394.	13.9	111
160	Extensively drug-resistant tuberculosis in long-term travellers. Lancet Infectious Diseases, The, 2016, 16, 642-643.	4.6	2
161	State-of-the-art series on tuberculosis and migration. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1280-1281.	0.6	7
162	Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis. Respiration, 2016, 92, 199-214.	1.2	18

#	Article	IF	Citations
163	Pulmonary Disease Caused by Non-Tuberculous Mycobacteria. Respiration, 2016, 91, 386-402.	1.2	114
164	When is a non-tuberculous mycobacterial infection a pulmonary disease?. International Journal of Tuberculosis and Lung Disease, 2016, 20, 855-856.	0.6	2
165	Thermostability of IFN-Î³ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet study. Tuberculosis, 2016, 98, 7-12.	0.8	7
166	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2016, 62, 887-895.	2.9	64
167	Personalized medicine for patients with MDR-TB: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 852-855.	1.3	31
168	Editorial Commentary: 1, 2, 3 (Years)â€ˆâ€ˆâ€¦â€ˆâ€ˆand You're Out: The End of a 123-year Historic Era. Clinical Infectious Diseases, 2016, 62, 1089-1091.	2.9	1
169	Lipoarabinomannan-Responsive Polycytotoxic T Cells Are Associated with Protection in Human Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 345-355.	2.5	57
170	Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimerâ€™s disease with OSBPL6, PTPRG, and PDCL3. Molecular Psychiatry, 2016, 21, 1608-1612.	4.1	97
171	Utilizing the Jaccard index to reveal population stratification in sequencing data: a simulation study and an application to the 1000 Genomes Project. Bioinformatics, 2016, 32, 1366-1372.	1.8	43
172	Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement. International Journal of Tuberculosis and Lung Disease, 2016, 20, 24-42.	0.6	123
173	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. European Respiratory Journal, 2016, 47, 45-68.	3.1	654
174	Exome Sequencing Analysis in Severe, Early-Onset Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1353-1363.	2.5	46
175	Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Molecular Psychiatry, 2016, 21, 270-276.	4.1	49
176	Clinical Application of Interferon-Î³ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathogens and Immunity, 2016, 1, 308.	1.4	16
177	Tuberculosis preventive chemotherapy: the times they are a-changin'. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1002-1002.	0.6	0
178	A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. BMC Genetics, 2015, 16, 138.	2.7	119
179	Cure Not Possible, by Definition. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1255-1256.	2.5	3
180	Multidrug-Resistant Tuberculosis in Europe, 2010â€“2011. Emerging Infectious Diseases, 2015, 21, 409-416.	2.0	75

#	Article	IF	Citations
181	Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection. Emerging Infectious Diseases, 2015, 21, 1685-1687.	2.0	4
182	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1836-1838.	3.1	28
183	Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. European Respiratory Journal, 2015, 45, 1081-1088.	3.1	44
184	False-negative interferon-Î³ release assay results in active tuberculosis: a TBNET study. European Respiratory Journal, 2015, 45, 279-283.	3.1	36
185	Risk Assessment of Tuberculosis in Contacts by IFN-Î³ Release Assays. A Tuberculosis Network European Trials Group Study. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1176-1184.	2.5	101
186	Childhood BCG vaccination does not influence control of Mycobacterium tuberculosis growth by human bronchoalveolar lavage cells. Tuberculosis, 2015, 95, 321-327.	0.8	1
187	PLD3 gene variants and Alzheimer's disease. Nature, 2015, 520, E7-E8.	13.7	60
188	T-Cell Therapy: Options for Infectious Diseases: Table 1.. Clinical Infectious Diseases, 2015, 61, S217-S224.	2.9	42
189	Adjusting heterogeneous ascertainment bias for genetic association analysis with extended families. BMC Medical Genetics, 2015, 16, 62.	2.1	9
190	Revisiting Healthcare Workers as a Risk Group for Progression toward Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1021-1022.	2.5	1
191	Ascertaining in vivo virulence of <I>Mycobacterium tuberculosis</I> lineages in patients in Mbeya, Tanzania. International Journal of Tuberculosis and Lung Disease, 2015, 19, 70-73.	0.6	2
192	Multidrug-resistant tuberculosis in Ukraine at a time of military conflict. International Journal of Tuberculosis and Lung Disease, 2015, 19, 492-493.	0.6	11
193	Treatment of Tuberculosis. New England Journal of Medicine, 2015, 373, 2149-2160.	13.9	290
194	Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1524-1527.	0.6	23
195	Nosocomial transmission of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1520-1523.	0.6	26
196	Novel drugs against tuberculosis: a clinician's perspective. European Respiratory Journal, 2015, 45, 1119-1131.	3.1	67
197	Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Molecular Psychiatry, 2015, 20, 337-344.	4.1	246
198	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Human Molecular Genetics, 2015, 24, 1200-1210.	1.4	43

#	Article	IF	Citations
199	Combined Antigen-Specific Interferon-Î³ and Interleukin-2 Release Assay (FluoroSpot) for the Diagnosis of Mycobacterium tuberculosis Infection. PLoS ONE, 2015, 10, e0120006.	1.1	11
200	Using Network Methodology to Infer Population Substructure. PLoS ONE, 2015, 10, e0130708.	1.1	0
201	Attitudes about Tuberculosis Prevention in the Elimination Phase: A Survey among Physicians in Germany. PLoS ONE, 2014, 9, e112681.	1.1	20
202	The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.5	40
203	Rare autosomal copy number variations in early-onset familial Alzheimerâ€™s disease. Molecular Psychiatry, 2014, 19, 676-681.	4.1	81
204	Integrated Pathway-Based Approach Identifies Association between Genomic Regions at CTCF and CACNB2 and Schizophrenia. PLoS Genetics, 2014, 10, e1004345.	1.5	44
205	Preventive chemotherapy for contacts of MDR-TB: is the proof in the pudding?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1262-1263.	0.6	0
206	Fluoroquinolone resistance in <I>Mycobacterium tuberculosis.</I> What have we learnt? [Editorial]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1-2.	0.6	7
207	Beyond GWAS in COPD: Probing the Landscape between Gene-Set Associations, Genome-Wide Associations and Protein-Protein Interaction Networks. Human Heredity, 2014, 78, 131-139.	0.4	18
208	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	3.1	256
209	Early BCG vaccination is unrelated to pulmonary immunity againstMycobacterium tuberculosisin adults. European Respiratory Journal, 2014, 44, 1087-1090.	3.1	6
210	Bifunctional T-Cell-Derived Cytokines for the Diagnosis of Tuberculosis and Treatment Monitoring. Respiration, 2014, 88, 251-261.	1.2	16
211	Pulmonary Erythema Migrans?. Respiration, 2014, 87, 252-253.	1.2	1
212	Multidrug-Resistant Tuberculosis. , 2014, , 239-253.		3
213	Progress in tuberculosis vaccine development and host-directed therapiesâ€”a state of the art review. Lancet Respiratory Medicine,the, 2014, 2, 301-320.	5.2	195
214	FARVAT: a family-based rare variant association test. Bioinformatics, 2014, 30, 3197-3205.	1.8	34
215	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1168-1176.	2.5	196
216	Getting Personal Perspectives on Individualized Treatment Duration in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 374-383.	2.5	39

#	Article	IF	Citations
217	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	2.9	116
218	Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respiratory Medicine,the, 2014, 2, 214-225.	5.2	291
219	Beyond the IFN-Â horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. European Respiratory Journal, 2014, 43, 1472-1486.	3.1	135
220	A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics Journal, 2014, 14, 41-47.	0.9	46
221	Linezolid in the treatment of drug-resistant tuberculosis: the way forward?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 631-632.	0.6	1
222	Development of a One-Step Probe Based Molecular Assay for Rapid Immunodiagnosis of Infection with M. tuberculosis Using Dried Blood Spots. PLoS ONE, 2014, 9, e105628.	1.1	18
223	Time to Culture Positivity and Sputum Smear Microscopy during Tuberculosis Therapy. PLoS ONE, 2014, 9, e106075.	1.1	38
224	Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/Ã–AG) (AWMF 055/066). Infection, 2013, 41, 91-115.	2.3	37
225	Tuberculosis: Current state of knowledge. Respirology, 2013, 18, 1047-1055.	1.3	14
226	Diagnosis and treatment of latent infection with <scp>M</scp>ycobacterium tuberculosis. Respirology, 2013, 18, 205-216.	1.3	40
227	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	3.1	226
228	Comparison of molecular and immunological methods for the rapid diagnosis of smear-negative tuberculosis. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1459-1465.	0.6	12
229	Clade-Specific Virulence Patterns of Mycobacterium tuberculosis Complex Strains in Human Primary Macrophages and Aerogenically Infected Mice. MBio, 2013, 4, .	1.8	136
230	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	3.1	346
231	Relationship between chemokine receptor expression, chemokine levels and HIV â€¡ replication in the lungs of persons exposed to M ycobacterium tuberculosis. European Journal of Immunology, 2013, 43, 540-549.	1.6	19
232	Dendritic cell recruitment in response to skin antigen tests in HIV-1-infected individuals correlates with the level of T-cell infiltration. Aids, 2013, 27, 1071-1080.	1.0	6
233	Adult Patients With Nosocomial Pneumonia. Deutsches Ärzteblatt International, 2013, 110, 634-40.	0.6	26
234	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	3.9	430

#	Article	IF	Citations
235	Plasmacytoid Dendritic Cells Infiltrate the Skin in Positive Tuberculin Skin Test Indurations. Journal of Investigative Dermatology, 2012, 132, 114-123.	0.3	24
236	"Interferon-Â release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis." M. Sester, G. Sotgiu, C. Lange, C. Giehl, E. Girardi, G.B. Migliori, A. Bossink, K. Dheda, R. Diel, J. Dominguez, M. Lipman, J. Nemeth, P. Ravn, S. Winkler, E. Huitric, A. Sandgren and D. Manissero. Eur Respir J 2011; 37: 100-111.. European Respiratory Journal, 2012, 39, 793-793.	3.1	2
237	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. European Respiratory Journal, 2012, 40, 990-1013.	3.1	211
238	Immunological Evidence of Incipient Pulmonary Tuberculosis. Journal of Infectious Diseases, 2012, 206, 1630-1631.	1.9	4
239	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. European Respiratory Journal, 2012, 40, 500-503.	3.1	9
240	Increased frequencies of pulmonary regulatory T-cells in latentMycobacterium tuberculosisinfection. European Respiratory Journal, 2012, 40, 1450-1457.	3.1	31
241	TB or not TB: The role of immunodiagnosis. European Journal of Immunology, 2012, 42, 2840-2843.	1.6	2
242	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. European Respiratory Journal, 2012, 39, 619-625.	3.1	74
243	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	3.1	188
244	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 2012, 21, 947-957.	1.4	216
245	Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review. PLoS ONE, 2012, 7, e47370.	1.1	29
246	Tbnet â€" Collaborative research on tuberculosis in Europe. European Journal of Microbiology and Immunology, 2012, 2, 264-274.	1.5	15
247	Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7853-7858.	3.3	306
248	Treatment of TB. , 2012, , 154-166.		9
249	Interferon-Â release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 88-99.	3.1	490
250	Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression. Journal of Leukocyte Biology, 2011, 90, 377-388.	1.5	71
251	Treatment of latent infection with Mycobacterium tuberculosis: update 2010. European Respiratory Journal, 2011, 37, 690-711.	3.1	104
252	Increased Expression of Beta-Defensin 1 (DEFB1) in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2011, 6, e21898.	1.1	65

#	Article	IF	Citations
253	Diagnosis of tuberculosis in patients with psoriasis: the need for a modified approach. European Respiratory Journal, 2011, 38, 232-233.	3.1	1
254	Impact of aMycobacterium tuberculosis-specific interferon-Î³ release assay in bronchoalveolar lavage fluid for a rapid diagnosis of tuberculosis. Journal of Internal Medicine, 2011, 270, 254-262.	2.7	16
255	S100A7/psoriasin expression in the human lung: unchanged in patients with COPD, but upregulated upon positive S. aureusdetection. BMC Pulmonary Medicine, 2011, 11, 10.	0.8	17
256	Intention to Test Is Intention to Treat. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 3-4.	2.5	20
257	Interferon-Â release assays for the diagnosis of latent Mycobacterium tuberculosis infection. European Respiratory Journal, 2011, 38, 1238-1239.	3.1	2
258	Treatment of tuberculosis: update 2010. European Respiratory Journal, 2011, 37, 441-462.	3.1	92
259	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal, 2011, 38, 730-733.	3.1	47
260	Interferon-Â release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 100-111.	3.1	488
261	Preventing and managing antimicrobial resistance: imperative for chest physicians. European Respiratory Journal, 2011, 37, 978-981.	3.1	21
262	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. European Respiratory Journal, 2011, 38, 1221-1223.	3.1	52
263	Interferon-Â release assays for diagnosis of active pleural tuberculosis: a developing world perspective. European Respiratory Journal, 2011, 38, 747-748.	3.1	5
264	Vitamin D and Active Tuberculosis: A Futile Quest?. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 95-95.	2.5	0
265	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	1.2	18
266	Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection. European Respiratory Journal, 2010, 36, 1242-1247.	3.1	39
267	In vitro naÃ¯ve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. Clinical Immunology, 2010, 136, 400-408.	1.4	8
268	Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nature Genetics, 2010, 42, 200-202.	9.4	348
269	Advances in the diagnosis of tuberculosis. Respirology, 2010, 15, 220-240.	1.3	130
270	Potential Role for IL-2 ELISpot in Differentiating Recent and Remote Infection in Tuberculosis Contact Tracing. PLoS ONE, 2010, 5, e11670.	1.1	25

#	Article	IF	Citations
271	The European Respiratory Journal targets tuberculosis. European Respiratory Journal, 2010, 36, 714-715.	3.1	5
272	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. European Respiratory Journal, 2010, 36, 208-211.	3.1	22
273	Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. Thorax, 2010, 65, 842-842.	2.7	1
274	From the authors:. European Respiratory Journal, 2010, 35, 938-940.	3.1	4
275	Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. European Respiratory Journal, 2010, 35, 619-626.	3.1	73
276	Assessing the Genotyping Quality of Different SNP-Chips and Imputed Data Using Family-Data. International Conference on Bioinformatics and Biomedical Engineering: [proceedings] International Conference on Bioinformatics and Biomedical Engineering, 2010, , .	0.0	0
277	Tuberculosis contact investigation in low prevalence countries: a European consensus. European Respiratory Journal, 2010, 36, 925-949.	3.1	234
278	Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. European Respiratory Journal, 2010, 36, 135-142.	3.1	119
279	Extensively drug-resistant tuberculosis: back to the future. European Respiratory Journal, 2010, 36, 475-477.	3.1	39
280	Xenotropic Murine Leukemia Virusâ€“related Gammaretrovirus in Respiratory Tract. Emerging Infectious Diseases, 2010, 16, 1000-1002.	2.0	36
281	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 289-290.	2.5	2
282	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal, 2010, 36, 1185-1206.	3.1	444
283	TB or not TB: update from the ERS Respiratory Infection Assembly 10. European Respiratory Journal, 2010, 36, 665-670.	3.1	5
284	What About Existing Databases?. Deutsches Ärzteblatt International, 2010, 107, 435-6; author reply 436.	0.6	0
285	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 387-393.	3.1	170
286	Association between Tuberculin Skin Test Reactivity, the Memory CD4 Cell Subset, and Circulating FoxP3-Expressing Cells in HIV-Infected Persons. Journal of Infectious Diseases, 2009, 199, 702-710.	1.9	34
287	HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1262-1270.	2.5	138
288	Vitamin D and Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 740-742.	2.5	18

#	Article	IF	Citations
289	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 666-673.	2.5	125
290	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	1.3	10
291	Interferon-Â release assays for the diagnosis of active tuberculosis: sensible or silly?. European Respiratory Journal, 2009, 33, 1250-1253.	3.1	66
292	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. European Respiratory Journal, 2009, 33, 956-973.	3.1	487
293	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	3.1	30
294	Consensus Not Yet Reached on Key Drugs for Extensively Drugâ€Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	2.9	6
295	Antimycobacterial immune responses in patients with pulmonary sarcoidosis. Clinical Respiratory Journal, 2009, 3, 229-238.	0.6	21
296	Integration of Genomic and Genetic Approaches Implicates IREB2 as a COPD Susceptibility Gene. American Journal of Human Genetics, 2009, 85, 493-502.	2.6	139
297	Defining priorities: swine-origin H1N1 and the MDR-TB epidemic. Lancet, The, 2009, 373, 2108.	6.3	10
298	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. Clinics in Chest Medicine, 2009, 30, 637-665.	0.8	64
299	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	3.1	163
300	Rapid Diagnosis of CNS Tuberculosis by a T-Cell Interferon-Î³ Release Assay on Cerebrospinal Fluid Mononuclear Cells. Infection, 2008, 36, 597-600.	2.3	40
301	Suttonsâ€™s Law: Local Immunodiagnosis of Tuberculosis. Infection, 2008, 36, 510-514.	2.3	21
302	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	3.1	131
303	Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey. European Respiratory Journal, 2008, 32, 1023-1030.	3.1	51
304	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	2.9	35
305	Local immunodiagnosis of pulmonary tuberculosis by enzyme-linked immunospot. European Respiratory Journal, 2008, 31, 261-265.	3.1	76
306	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	3.1	67

#	Article	IF	Citations
307	Rapid diagnosis of pulmonary TB by BAL enzyme-linked immunospot assay in an immunocompromised host. European Respiratory Journal, 2008, 31, 1132-1135.	3.1	28
308	Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1000-1001.	2.5	16
309	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. Emerging Infectious Diseases, 2008, 14, 1700-1706.	2.0	113
310	Tuberculosis, one disease, many faces. Monaldi Archives for Chest Disease, 2008, 69, 2-4.	0.3	7
311	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. PLoS ONE, 2008, 3, e3417.	1.1	88
312	Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. International Journal of Tuberculosis and Lung Disease, 2008, 12, 651-7.	0.6	69
313	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	3.1	179
314	Rapid immunodiagnosis of tuberculosis in a woman receiving anti-TNF therapy. Nature Clinical Practice Rheumatology, 2007, 3, 528-534.	3.2	21
315	Use of a T-cell interferon-Â release assay for the diagnosis of tuberculous pleurisy. European Respiratory Journal, 2007, 30, 1173-1179.	3.1	150
316	Rapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 317-317.	2.5	0
317	Extensively Drug-resistant Tuberculosis, Italy and Germany. Emerging Infectious Diseases, 2007, 13, 780-782.	2.0	96
318	Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clinical Microbiology and Infection, 2007, 13, 510-515.	2.8	33
319	Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respiratory Research, 2006, 7, 77.	1.4	85
320	The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood, 2006, 108, 965-973.	0.6	333
321	Cost-optimisation of screening for latent tuberculosis in close contacts. European Respiratory Journal, 2006, 28, 35-44.	3.1	82
322	Rapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1048-1054.	2.5	148
323	Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. European Respiratory Journal, 2006, 28, 16-23.	3.1	61
324	Fatal Outcome of a Hyperinfection Syndrome despite Successful Eradication of Strongyloides with Subcutaneous Ivermectin. Infection, 2005, 33, 383-386.	2.3	46

#	Article	IF	Citations
325	Family-based association tests for survival and times-to-onset analysis. Statistics in Medicine, 2004, 23, 179-189.	0.8	45
326	Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology, 2004, 112, 531-542.	2.0	57
327	Disseminated Mycobacterium avium-intracellulare Complex (MAC) Infection in the Era of Effective Antiretroviral Therapy. Drugs, 2004, 64, 679-692.	4.9	27
328	Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. Aids, 2004, 18, 605-613.	1.0	14
329	A Family-Based Association Test for Repeatedly Measured Quantitative Traits Adjusting for Unknown Environmental and/or Polygenic Effects. Statistical Applications in Genetics and Molecular Biology, 2004, 3, 1-27.	0.2	78
330	Using the Noninformative Families in Family-Based Association Tests: A Powerful New Testing Strategy. American Journal of Human Genetics, 2003, 73, 801-811.	2.6	80
331	Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2003, 51, 1-4.	1.3	52
332	A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics, 2003, 4, 195-206.	0.9	181
333	Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. Aids, 2003, 17, 2015-2023.	1.0	172
334	Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood, 2003, 101, 226-235.	0.6	167
335	A New Powerful Non-Parametric Two-Stage Approach for Testing Multiple Phenotypes in Family-Based Association Studies. Human Heredity, 2003, 56, 10-17.	0.4	54
336	Impact of Suppression of Viral Replication by Highly Active Antiretroviral Therapy on Immune Function and Phenotype in Chronic HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 33-40.	0.9	4
337	CD4+ T-Lymphocyte Nadir and the Effect of Highly Active Antiretroviral Therapy on Phenotypic and Functional Immune Restoration in HIV-1 Infection. Clinical Immunology, 2002, 102, 154-161.	1.4	100
338	Power Calculations for a General Class of Family-Based Association Tests: Dichotomous Traits. American Journal of Human Genetics, 2002, 71, 575-584.	2.6	118
339	Power and Design Considerations for a General Class of Family-Based Association Tests: Quantitative Traits. American Journal of Human Genetics, 2002, 71, 1330-1341.	2.6	138
340	On a general class of conditional tests for family-based association studies in genetics: the asymptotic distribution, the conditional power, and optimality considerations. Genetic Epidemiology, 2002, 23, 165-180.	0.6	108
341	Destructive Osteoarthritis after Delayed Diagnosis of Tuberculosis. Infection, 2002, 30, 46-49.	2.3	17
342	CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood, 2001, 98, 156-164.	0.6	147

#	Article	IF	Citations
343	On Prediction of Genetic Values in Marker-Assisted Selection. Genetics, 2001, 159, 1375-1381.	1.2	27
344	Tuberkulose: Neue Therapieformen. , 0, , .		0